價(jià)格 | ¥1280 | ¥1980 | ¥2900 |
包裝 | 50ul | 100ul | 200ul |
最小起訂量 | 50ul |
發(fā)貨地 | 上海 |
更新日期 | 2025-01-17 |
中文名稱(chēng):Anti-phospho-IRS1 (Ser307) antibody-磷酸化胰島素受體底物1 p-IRS-1/2抗體 | 英文名稱(chēng):phospho-IRS1 (Ser307) |
品牌: 滬震生物 | 產(chǎn)地: 中國(guó)/上海 |
保存條件: -20°C | 純度規(guī)格: > 99% |
產(chǎn)品類(lèi)別: 抗體 一抗 | |
抗體名: IRS1 (phospho S307); p-IRS-1; IRS1(phospho-Ser307); IRS1_HUMAN; Insulin receptor substrate 1; IRS-1; IRS 1; | 靶點(diǎn): 詳見(jiàn)說(shuō)明書(shū) |
宿主: Rabbit | 適應(yīng)物種: 詳見(jiàn)說(shuō)明書(shū) |
克隆性: 詳見(jiàn)說(shuō)明書(shū) | 濃度: 1mg/ml |
應(yīng)用范圍: ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1μg /test IF=1:100-500 (石蠟切片需做抗原修復(fù)) not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. | 標(biāo)識(shí)物: 詳見(jiàn)說(shuō)明書(shū) |
形態(tài): 液體 | 亞型: IgG |
免疫原: 詳見(jiàn)說(shuō)明書(shū) | 貨號(hào): Hz-R2736 |
用途范圍: 科研使用 | 規(guī)格: 50ul/100ul/200ul |
是否進(jìn)口: 否 | 是否單克隆: 詳見(jiàn)說(shuō)明書(shū) |
保質(zhì)期: 12個(gè)月 | 抗原來(lái)源: 詳見(jiàn)說(shuō)明書(shū) |
標(biāo)記物: 詳見(jiàn)說(shuō)明書(shū) | 產(chǎn)品用途: ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1μg /test IF=1:100-500 (石蠟切片需做抗原修復(fù)) not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
Rabbit Anti-phospho-IRS1 (Ser307) Polyclonal Antibody
DATASHEET
Host:Rabbit
Target Protein:phospho-IRS1 (Ser307)
IR:Immunogen Range:TE(p-S)IT
Clonality:Polyclonal
Isotype:IgG
Entrez Gene:3667
Swiss Prot:P35568
Source:KLH conjugated Synthesised phosphopeptide derived from human IRS1 around the phosphorylation site of Ser307:TE(p-S)IT
Purification:affinity purified by Protein A
Storage:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
Background:Insulin receptor substrates (IRS) are responsible for several insulin related activities, such as glucose homeostasis, cell growth, cell transformation, apoptosis and insulin signal transduction. Serine/threonine phosphorylation of IRS1 has been demonstrated to be a negative regulator of insulin signaling and is responsible for its degradation, although IRS1 degradation pathways are not well understood. IRS1 has also been shown to be constitutively activated in cancers such as breast cancer, Wilm's tumors, and adrenal cortical carcinomas, thus making IRS1 phosphorylation and subsequent degradation an attractive therapeutic target. To date there have been four subtypes identified: IRS1, 2, 3 and 4, with IRS1 being widely expressed.
Size:50ul
Concentration:1mg/ml
Applications:ELISA(1:5000-10000)
IHC-P(1:100-500)
IHC-F(1:100-500)
Flow-Cyt(1μg /test)
IF(1:100-500)
Cross Reactive Species:Human
Mouse
Rat
Dog
Pig
Cow
Horse
Rabbit
僅供科研使用。不能用于人和動(dòng)物治療等其它臨床診斷用!
成立日期 | 2014-05-08 (11年) | 注冊(cè)資本 | 100萬(wàn)元整 |
員工人數(shù) | 10-50人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以?xún)?nèi) |
主營(yíng)行業(yè) | 生化試劑,細(xì)胞培養(yǎng),蛋白組學(xué),分子生物學(xué),細(xì)胞生物學(xué) | 經(jīng)營(yíng)模式 | 工廠(chǎng),試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢(xún)價(jià) |
VIP4年
|
上海冠導(dǎo)生物工程有限公司
|
2025-01-26 | |
¥3104 |
VIP4年
|
上海博爾森生物科技有限公司
|
2025-01-17 | |
¥2460 |
VIP6年
|
上海澤葉生物科技有限公司
|
2025-01-20 |